Mutations of optineurin in amyotrophic lateral sclerosis

…, K Kobatake, N Morimoto, K Abe, N Suzuki, M Aoki… - Nature, 2010 - nature.com
Amyotrophic lateral sclerosis (ALS) has its onset in middle age and is a progressive disorder
characterized by degeneration of motor neurons of the primary motor cortex, brainstem and …

Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy

J Liu, M Aoki, I Illa, C Wu, M Fardeau, C Angelini… - Nature …, 1998 - nature.com
Miyoshi myopathy (MM) is an adult onset, recessive inherited distal muscular dystrophy that
we have mapped to human chromosome 2p13. We recently constructed a 3-Mb P1-derived …

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

…, RF Simm, AMM Lino, T Misu, MI Leite, M Aoki… - Neurology, 2014 - AAN Enterprises
Objective: To evaluate clinical features among patients with neuromyelitis optica spectrum
disorders (NMOSD) who have myelin oligodendrocyte glycoprotein (MOG) antibodies, …

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

K Abe, M Aoki, S Tsuji, Y Itoyama, G Sobue… - The Lancet …, 2017 - thelancet.com
Background In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS),
edaravone did not show a significant difference in the Revised ALS Functional Rating Scale …

The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin

…, T Yanagisawa, M Watanabe, Y Ikeda, M Aoki… - Nature …, 2001 - nature.com
The newly recognized ataxia–ocular apraxia 1 (AOA1; MIM 208920) 1 , 2 , 3 , 4 is the most
frequent cause of autosomal recessive ataxia in Japan 2 , 4 , 5 , 6 , 7 , 8 , 9 and is second only …

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

K Abe, Y Itoyama, G Sobue, S Tsuji, M Aoki… - … Lateral Sclerosis and …, 2014 - Taylor & Francis
Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral
sclerosis (ALS) patients. We conducted a 36-week confirmatory study, consisting of 12-week pre-…

MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy

…, S Nishiyama, T Misu, H Kuroda, M Aoki… - Neurology …, 2017 - AAN Enterprises
Objective: To describe the features of adult patients with benign, unilateral cerebral cortical
encephalitis positive for the myelin oligodendrocyte glycoprotein (MOG) antibody. Methods: …

Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent

…, R Nakamura, T Akiyama, S Hadano, M Aoki… - Nature medicine, 2018 - nature.com
Amyotrophic lateral sclerosis (ALS) is a heterogeneous motor neuron disease for which no
effective treatment is available, despite decades of research into SOD1-mutant familial ALS (…

Rats expressing human cytosolic copper–zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron …

M Nagai, M Aoki, I Miyoshi, M Kato… - Journal of …, 2001 - Soc Neuroscience
Some cases of familial amyotrophic lateral sclerosis (ALS) are caused by mutations in the
gene encoding cytosolic, copper–zinc superoxide dismutase (SOD1). We report here that rats …

Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study

…, M Konno, K Suzuki, S Takahashi, H Fukuda, M Aoki… - Brain, 2012 - academic.oup.com
Dementia is one of the most debilitating symptoms of Parkinson's disease. A recent
longitudinal study suggests that up to 80% of patients with Parkinson's disease will eventually …